Gastroparesis Consortium Continuation and New Type 2 Diabetes Mellitus Studiies

胃轻瘫联盟延续和新型 2 型糖尿病研究

• 批准号: 8545795
• 负责人: KENNETH L KOCH
• 金额: $ 30.24万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-15 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8545795
• 关键词: Abdominal Pain; Affect; Age; Biopsy; Chronic; Classification; Clinic; Clinical; Clinical Data; Clinical Research; Data; Data Coordinating Center; Databases; Defect; Diagnosis; Disease; Endocrine; Enrollment; Epidemiology; Etiology; GNAI2 gene; Gastric Emptying; Gastric Pacemakers; Gastrointestinal tract structure; Gastroparesis; Gender; Genetic; Goals; Hormones; Hunger; Hyperglycemia; Individual; Institutes; Insulin Infusion Systems; Knowledge; Lead; Learning; Maintenance; Malnutrition; Manuscripts; Measures; Metabolic; Metabolic Control; Methods; Molecular; Morbidity - disease rate; National Institute of Diabetes and Digestive and Kidney Diseases; Natural History; Nausea; Nausea and Vomiting; Non-Insulin-Dependent Diabetes Mellitus; Nortriptyline; Nutritional Support; Obesity; Outcome; Pathogenesis; Pathology; Patients; Physicians; Pilot Projects; Placebos; Prediabetes syndrome; Principal Investigator; Property; Protocols documentation; Public Health; Publications; Quality of life; Questionnaires; Race; Recruitment Activity; Registries; Research; Resources; Risk; Safety; Satiation; Series; Severities; Site; Staging; Stomach; Symptoms; Syndrome; Thick; Time; Tissues; United States National Institutes of Health; Universities; Visit; Work; abstracting; aprepitant; base; blood glucose regulation; cell motility; design; diabetic gastroparesis; follow-up; forest; gastrointestinal; ghrelin; glucagon-like peptide 1; glucose monitor; improved; insight; insulin secretion; mortality; neuromuscular; patient registry; programs; randomized trial; response; treatment response; treatment strategy; treatment trial; young woman

DESCRIPTION (provided by applicant): This proposal from Wake Forest University is to continue as a Clinical Center in the Gastoparesis Clinical Research Consortium (GpCRC) and to continue our excellent follow up and retention of the 105 patients we have thus far recruited to the Registry. In addition, we will continue enrollment into the Registry and complete three treatment trials (NORIG, GLUMIT-DG, APRON). We will also utilize the resources of the Consortium and the Registry to continue to investigate the etiology, epidemiology, and morbidity and mortality associated with gastroparesis. Our center will support the Pathological Basis of Gastroparesis Study conducted by Dr. Farrugia at the Mayo Clinic in Rochester, MN for identification of the molecular factors involved in pathogenesis of gastroparesis as we institute a program of gastric stimulator therapy. The goal of the GpCRC sponsored by the NIDDK since 2006 is to focus on the etiology, treatment strategies, and clinical course of gastroparesis and we will continue to support the Consortium and Data Coordinating Center (DCC) in designing and carrying out the protocols, providing data in a timely manner to the DCC, developing publication priorities, and creating abstracts and manuscripts for publication. Our site will continue to participate fully in all Coordinator and Steering Committee activities. We will also continue to work efficiently with the NIDDK Biosample, Genetic and Data Repositories. Patients with Type 2 diabetes mellitus (T2DM) develop gastroparesis and associated symptoms. Our site specific proposal is to investigate gastric motility and neuro-endocrinological abnormalities in patients with Type 2 diabetes. We hypothesize that these neuro-endocrine defects affect; a) myoelectrical and contractile properties of the stomach and, b) the release of gut hormones which control insulin secretions and hunger and satiety (GLP-1, GIP, ghrelin, VIP and NPY) in a differential manner over time. We propose to investigate the gastric neuromuscular and the endocrinologic reponses to a mixed meal in individuals ranging from pre-diabetes to late Type 2 diabetes (>10 years since diagnosis).

描述（由申请人提供）：这项来自维克森林大学的提议是继续作为胃瘫临床研究联盟（GpCRC）的临床中心，并继续我们出色的随访和保留我们迄今已招募到注册中心的105名患者。此外，我们将继续入组注册并完成三项治疗试验（NORIG、GLUMIT-DG、APRON）。我们还将利用联盟和注册中心的资源继续调查胃轻瘫的病因学、流行病学、发病率和死亡率。本中心将支持Farrugia博士在明尼苏达州罗切斯特市梅奥诊所进行的胃轻瘫病理基础研究，以确定胃轻瘫发病机制中的分子因素，同时我们将制定胃刺激疗法计划。GpCRC的目标是关注胃轻瘫的病因、治疗策略和临床过程，我们将继续支持联盟和数据协调中心（DCC）设计和执行协议，及时向DCC提供数据，制定出版优先事项，并创建摘要和手稿以供发表。我们的网站将继续充分参与所有协调员和指导委员会的活动。我们还将继续有效地与NIDDK生物样本，遗传和数据存储库合作。2型糖尿病（T2DM）患者出现胃轻瘫及相关症状。我们的具体建议是研究2型糖尿病患者的胃运动和神经内分泌异常。我们假设这些神经内分泌缺陷影响；a)胃的肌电和收缩特性，b)随时间以不同的方式释放控制胰岛素分泌和饥饿和饱腹感的肠道激素（GLP-1， GIP, ghrelin， VIP和NPY）。我们建议研究从糖尿病前期到晚期2型糖尿病（诊断后10年）的个体对混合膳食的胃神经肌肉和内分泌反应。